A Phase 3 interventional study of Rosuvastatin (Crestor) and Ezetimibe in Hypercholesterolemia, Coronary Heart Disease and Atherosclerosis, sponsored by AstraZeneca. Completed at 9 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 11th largest by enrollment of the 57 interventional ones that give a count, is the only one that started in 2007, is one of 33 in phase 3, and was the 14th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,743 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 203 across the 57 interventional studies. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
60 studies in Hypercholesterolemia by AstraZeneca: 3 open now, 3 under way, 3 of them phase 3. Of 55 finished, 7 (13%) have results posted.
Among the 60 studies in Hypercholesterolemia by AstraZeneca, this one is the 8th largest by enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2007, is one of 25 in phase 3, and was the 17th registered.
AstraZeneca’s Hypercholesterolemia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing rosuvastatin in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 60 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether treatment of Rosuvastatin (CRESTOR™) or Simvastatin given as monotherapy or given in combination with Ezetimibe, will lower the Low Density Lipoprotein Cholesterol (LDL-C) in patients with Hypercholesterolaemia and Coronary Heart Disease (CHD) or a CHD Risk Equivalent, Atherosclerosis or a 10-year CHD Risk of >20%
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
a myocardial infarction, recent episode of unstable angina, myocardial revascularisation [percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG) surgery or another revascularisation procedure] or a (TIA) or stroke and patients awaiting a planned myocardial revascularisation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10mg and 20 mg
10 mg
40mg and 80 mg
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment
Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment
Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment
Percent change in TC = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment
Percent change in TG = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment
Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment
Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment
Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in TC/HDL-C After 6 Weeks Combination Treatment
Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment
Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment
Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment
Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment
Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on combination therapy (Last observation carried forward)
Percent Change in LDL-C After 6 Weeks Monotherapy
Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value\*100
Time frame: Mean of Weeks 4 and 6 on monotherapy (Last observation carried forward)
Eight hundred thirty-three patients (with hypercholesterolaemia and CHD or CHD risk equivalent, atherosclerosis or a 10-year CHD risk of \>20%) were randomized into the study, from 111 sites located in the United States (56), Peru (13), Netherlands (12), Colombia (8), Argentina (8), Brazil (6), Chile (4) and Lithuania (4).
| Milestone | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Started | 214 | 214 | 202 | 203 |
| Completed | 195 | 186 | 183 | 188 |
| Not completed | 19 | 28 | 19 | 15 |
| Withdrew: Adverse event | 7 | 11 | 6 | 7 |
| Withdrew: Withdrawal by subject | 5 | 9 | 3 | 4 |
| Withdrew: Lost to follow-up | 4 | 2 | 4 | 0 |
| Withdrew: Incorrect enrolment/mis-randomisation | 1 | 2 | 1 | 2 |
| Withdrew: Severe non-compliance | 0 | 1 | 1 | 1 |
| Withdrew: Safety reasons | 1 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 3 | 3 | 1 |
Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment | -59.7200 ± 14.1660 | -63.4800 ± 16.6970 | -55.2200 ± 15.7500 | -57.4200 ± 20.4660 |
Percent change in HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment | 6.4100 ± 13.9340 | 7.4600 ± 16.3510 | 3.9200 ± 12.6830 | 4.3400 ± 12.6430 |
Percent change in TC = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment | -43.0000 ± 11.2080 | -46.6300 ± 12.8180 | -39.5600 ± 12.6640 | -41.7100 ± 15.1500 |
Percent change in TG = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment | -28.8500 ± 23.7090 | -35.0000 ± 23.9710 | -22.9500 ± 28.1390 | -25.8200 ± 26.6190 |
Percent change in nonHDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment | -54.6500 ± 13.6770 | -58.9100 ± 14.9320 | -49.9300 ± 14.7380 | -52.3700 ± 18.4290 |
Percent change in ApoB = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment | -46.1100 ± 12.6280 | -49.5000 ± 13.8210 | -41.9500 ± 14.7500 | -44.1700 ± 17.1790 |
Percent change in ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment | 3.8100 ± 13.0420 | 2.6800 ± 11.5020 | 1.4900 ± 9.6830 | 2.1300 ± 10.7410 |
Percent change in TC/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in TC/HDL-C After 6 Weeks Combination Treatment | -45.5200 ± 13.2280 | -49.4600 ± 13.5750 | -41.2700 ± 13.0210 | -43.4500 ± 16.3430 |
Percent change in LDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment | -61.4700 ± 15.5470 | -65.2500 ± 16.6800 | -57.1300 ± 14.7770 | -58.6600 ± 21.1300 |
Percent change in non-HDL-C/HDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment | -56.4200 ± 15.4150 | -60.8900 ± 15.5030 | -51.1100 ± 15.3800 | -53.5100 ± 20.2230 |
Percent change in ApoB/ApoA-1 = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment | -47.3900 ± 13.8690 | -50.2400 ± 14.2570 | -42.5400 ± 14.2480 | -44.7600 ± 17.8420 |
Percent change in hs-CRP = (Combination treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment | 107.1200 ± -99.0000 | -9.5300 ± -97.9000 | 15.0300 ± -91.5000 | 0.4200 ± -94.9000 |
Percent change in LDL-C = (Monotherapy treatment value - Baseline value)/Baseline value\*100
| Percentage | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 |
|---|---|---|---|---|
| Percent Change in LDL-C After 6 Weeks Monotherapy | -46.4900 ± 13.1080 | -53.5900 ± 10.5030 | -40.8600 ± 12.4130 | -46.3500 ± 16.1880 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rosuvastatin 10 mg | — | — | — |
| Rosuvastatin 20 mg | — | — | — |
| Simvastatin 40 mg | — | — | — |
| Simvastatin 80 mg | — | — | — |
| Rosu 10 mg + Eze 10 mg | — | — | — |
| Rosu 20 mg + Eze 10 mg | — | — | — |
| Simva 40 mg + Eze 10 mg | — | — | — |
| Simva 80 mg + Eze 10 mg | — | — | — |
| Event | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Simvastatin 40 mg | Simvastatin 80 mg | Rosu 10 mg + Eze 10 mg | Rosu 20 mg + Eze 10 mg | Simva 40 mg + Eze 10 mg | Simva 80 mg + Eze 10 mg |
|---|---|---|---|---|---|---|---|---|
| Angina unstableCardiac disorders | 0/213 | 0/212 | 0/199 | 0/203 | 2/200 | 0/191 | 3/189 | 0/192 |
| Cerebrovascular accidentNervous system disorders | 0/213 | 2/212 | 0/199 | 0/203 | 0/200 | 0/191 | 0/189 | 0/192 |
| Myocardial ischaemiaCardiac disorders | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 1/189 | 0/192 |
| Fracture displacementInjury, poisoning and procedural complications | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 1/189 | 0/192 |
| Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 1/189 | 0/192 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 1/189 | 0/192 |
| Staphylococcal abscessInfections and infestations | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 1/191 | 0/189 | 0/192 |
| AnaemiaBlood and lymphatic system disorders | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 0/189 | 1/192 |
| Abdominal abscessInfections and infestations | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 0/189 | 1/192 |
| DiverticulitisInfections and infestations | 0/213 | 0/212 | 0/199 | 0/203 | 0/200 | 0/191 | 0/189 | 1/192 |
| Event | Rosuvastatin 10 mg | Rosuvastatin 20 mg | Simvastatin 40 mg | Simvastatin 80 mg | Rosu 10 mg + Eze 10 mg | Rosu 20 mg + Eze 10 mg | Simva 40 mg + Eze 10 mg | Simva 80 mg + Eze 10 mg |
|---|---|---|---|---|---|---|---|---|
| MyalgiaMusculoskeletal and connective tissue disorders | 5/213 | 10/212 | 3/199 | 7/203 | 4/200 | 5/191 | 4/189 | 3/192 |
| NasopharyngitisInfections and infestations | 3/213 | 3/212 | 4/199 | 3/203 | 2/200 | 5/191 | 2/189 | 3/192 |
| HeadacheNervous system disorders | 4/213 | 4/212 | 5/199 | 4/203 | 3/200 | 1/191 | 1/189 | 2/192 |
| NauseaGastrointestinal disorders | 4/213 | 5/212 | 1/199 | 1/203 | 1/200 | 3/191 | 2/189 | 1/192 |
| DizzinessNervous system disorders | 1/213 | 5/212 | 1/199 | 2/203 | 1/200 | 2/191 | 3/189 | 2/192 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/213 | 4/212 | 1/199 | 4/203 | 2/200 | 0/191 | 1/189 | 2/192 |
| InfluenzaInfections and infestations | 2/213 | 1/212 | 4/199 | 1/203 | 0/200 | 4/191 | 3/189 | 0/192 |
| Oedema peripheralGeneral disorders | 0/213 | 0/212 | 0/199 | 0/203 | 1/200 | 0/191 | 2/189 | 4/192 |
| BronchitisInfections and infestations | 1/213 | 1/212 | 4/199 | 2/203 | 3/200 | 2/191 | 2/189 | 1/192 |
| Upper respiratory tract infectionInfections and infestations | 1/213 | 1/212 | 4/199 | 3/203 | 2/200 | 1/191 | 3/189 | 2/192 |
| Age Continuous(years) | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 | Total |
|---|---|---|---|---|---|
| Mean | 62.2 ± 10.14 | 61.8 ± 9.93 | 61.9 ± 9.37 | 62.1 ± 9.17 | 62.0 ± 9.66 |
| Sex: Female, Male(Participants) | R10 to R10 + E10 | R20 to R20 + E10 | S40 to S40 + E10 | S80 to S80 + E10 | Total |
|---|---|---|---|---|---|
| Female | 91.0000 | 97.0000 | 97.0000 | 90.0000 | 375.0 |
| Male | 123.0000 | 117.0000 | 105.0000 | 113.0000 | 458.0 |
The record gives a start of Aug 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Ezetimibe · Simvastatin